840p 0.0 0.0%
Last Trade - 16/08/19
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ686.0m |
| Position in Universe | th / 1841 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | TTM | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2019
|
31st Dec 2020
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BTG Limited, formerly BTG plc, is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.
| Last Annual | March 31st, 2019 |
| Last Interim | March 31st, 2019 |
| Incorporated | December 12, 1991 |
| Public Since | June 28, 1995 |
| No. of Shareholders: | 7,581 |
| No. of Employees: | 1,547 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | , |
| Exchange | London Stock Exchange |
| Shares in Issue | 388,257,291 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom |
| Web | https://www.btgplc.com/ |
| Phone | +44 20 75750000 |
| Contact | Andy Burrows (Vice President - Corporate and Investor Relations) |
| Auditors | Deloitte LLP |
